Rare Disease Report
Patients & Caregivers

Polycythemia Vera Case Study - Final Thoughts on Ruxolitinib

SEPTEMBER 13, 2016
Srdan Verstovsek, MD, PhD

Srdan Verstovsek, MD, PhD of the MD Anderson Cancer Center in Houston, Texas notes that in his experience, patients with polycythemia vera who are unresponsive to hydroxyurea tend to have much improves symptoms and quality of life once they begin ruxolitinib treatment.

Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.